Risky Business: Should the FDA Pay Attention to Pharmaceutical Prices?

11 Pages Posted: 18 May 2017 Last revised: 14 Jun 2017

See all articles by David A. Hyman

David A. Hyman

Georgetown University Law Center

William E. Kovacic

George Washington University - Law School; King's College London - The Dickson Poon School of Law

Date Written: May 18, 2017

Abstract

People are angry about drug prices. What role, if any, should the FDA play in addressing this issue? Historically, the FDA’s answer has been “not our problem.” As the quality and safety agency, the FDA has repeatedly refused to get involved in drug pricing matters, even when its actions (and inactions) have contributed to the problem. We examine the circumstances under which the FDA should pay attention to pharmaceutical prices, and discuss the implications of it doing so.

Keywords: FDA, drug pricing, drug quality, drug safety, generic drugs

JEL Classification: D73, K23, I18

Suggested Citation

Hyman, David A. and Kovacic, William E., Risky Business: Should the FDA Pay Attention to Pharmaceutical Prices? (May 18, 2017). GWU Law School Public Law Research Paper No. 2017-37, GWU Legal Studies Research Paper No. 2017-37, Available at SSRN: https://ssrn.com/abstract=2970683 or http://dx.doi.org/10.2139/ssrn.2970683

David A. Hyman (Contact Author)

Georgetown University Law Center ( email )

600 New Jersey Avenue, NW
Washington, DC 20001
United States

William E. Kovacic

George Washington University - Law School ( email )

2000 H Street, N.W.
Washington, DC 20052
United States
202.994.8123 (Phone)

HOME PAGE: http://www.law.gwu.edu/faculty/profile.aspx?id=1731

King's College London - The Dickson Poon School of Law

Somerset House East Wing
Strand
London, WC2R 2LS
United Kingdom

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
148
Abstract Views
938
rank
273,450
PlumX Metrics